A research team led by Prof. Wang Yi and Wei Haiming from the University of Science and Technology of China (USTC), in collaboration with Prof. Ding Chen's team from Human Phenome Institute at Fudan University, has elucidated ...
Sep 17, 2025
0
0
Patients with intermediate stage primary liver cancer who received a vaccine of dendritic cells saw a longer time without tumor progression in response to standard treatment, according to a new study led by the University ...
Aug 26, 2025
0
0
Researchers from the School of Biomedical Sciences at the LKS Faculty of Medicine, the University of Hong Kong (HKUMed), have made a significant advancement that could reshape the treatment landscape for hepatocellular carcinoma ...
Aug 13, 2025
0
9
Among the many forms of liver cancer, hepatocellular carcinoma (HCC) is the most common and one of the leading causes of cancer-related deaths worldwide. It is a complex disease with multiple aggressive subtypes that are ...
Aug 11, 2025
0
0
A new study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center may help explain why certain liver tumors return quickly after thermal ablation, a widely used minimally-invasive, image-guided technique ...
Jul 10, 2025
0
0
The National Cancer Institute and University of Oxford report that oral contraceptive use is not associated with increased liver cancer risk, based on a population-based analysis of more than 1.5 million women and a review ...
A novel molecular imaging agent targeting glypican-3 (GPC3) has demonstrated high sensitivity and specificity in detecting hepatocellular carcinoma (HCC), including tumors smaller than one centimeter, according to results ...
Jun 24, 2025
0
0
Hepatocellular carcinoma (HCC), the most common type of liver cancer and the third-leading cause of cancer-related deaths worldwide, is extremely challenging to treat. However, the future of HCC patient care looks brighter ...
Jun 23, 2025
0
0
A research team led by Prof. Li Hai from the Hefei Institutes of Physical Science of the Chinese Academy of Sciences has become the first to systematically explore how large language models (LLMs) can assist in predicting ...
Jun 18, 2025
0
0
A research team from the School of Clinical Medicine of the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) has pioneered the use of a 'dual immunotherapy' combination—nivolumab and ipilimumab (NIVO+IPI)—in ...
Jun 16, 2025
0
44
Hepatocellular carcinoma (HCC, also called malignant hepatoma) is the most common type of liver cancer. Most cases of HCC are secondary to either a viral hepatitide infection (hepatitis B or C) or cirrhosis (alcoholism being the most common cause of hepatic cirrhosis).
Compared to other cancers, HCC is quite a rare tumor in the United States. In countries where hepatitis is not endemic, most malignant cancers in the liver are not primary HCC but metastasis (spread) of cancer from elsewhere in the body, e.g., the colon. Treatment options of HCC and prognosis are dependent on many factors but especially on tumor size and staging. Tumor grade is also important. High-grade tumors will have a poor prognosis, while low-grade tumors may go unnoticed for many years, as is the case in many other organs, such as the breast, where a ductal carcinoma in situ (or a lobular carcinoma in situ) may be present without any clinical signs and without correlate on routine imaging tests, although in some occasions it may be detected on more specialized imaging studies like MR mammography.
This text uses material from Wikipedia licensed under CC BY-SA
